Remove solutions site-network-for-sponsors
article thumbnail

AGC and RoosterBio partner for cell and exosome therapy manufacturing

Pharmaceutical Technology

This approach will aid in creating an end-to-end solution for developing and producing human mesenchymal stem/stromal cell (hMSC) and exosome therapies. Its network of sites extends access to the newest cell therapy technologies and processes, including allogenic and autologous systems and methods.

article thumbnail

Top Site Challenges of 2023 – Data and Insights on Site Burden and Trial Efficiency

ACRP blog

This is a sponsored message. This increase in trial design complexity has added additional burden on clinical research sites, many of which are already facing unprecedented resourcing issues, enrollment challenges, increased technology burden, and more.

Trials 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top Site Challenges of 2023 – Data and Insights on Site Burden and Trial Efficiency

ACRP blog

This is a sponsored message. This increase in trial design complexity has added additional burden on clinical research sites, many of which are already facing unprecedented resourcing issues, enrollment challenges, increased technology burden, and more.

Trials 52
article thumbnail

Key operational considerations to optimise decentralised clinical trials

pharmaphorum

Now that the COVID-19 pandemic has provided the industry with a solid foundation of experience with decentralised trials, it is appropriate to reflect and ask whether DCT studies are truly helping to address long-standing issues in research and development for sponsors, study teams and, most importantly, patients.

article thumbnail

2 Strategies For Starting Your Own CRO in Clinical Research

Clinical Trial Gurus

One solution to this problem is to focus on opening a site and then work on establishing the new site as a leader in a specific area while networking with other sites. Large CROs tend to take larger contracts which makes it more difficult for anyone to open a new CRO and get ahead.

article thumbnail

WCG Launches 360 Protocol Assessment™ Solution to Ensure Protocol Quality by Design

WCG Clinical

WCG’s quality, operations, and diversity, equity and inclusion subject matter experts identify potential areas of risk in conjunction with its vast network of investigators, sites, and patient advocacy groups to ensure all key stakeholder input is received.

article thumbnail

The next phase of decentralisation in clinical trials

Pharmaceutical Technology

Rather than bringing patients to sites, study teams are now exploring ways they can bring the trial to patients using a varying combination of direct-to-patient drug shipments, home nursing, video conferencing, and electronic data collection. There is data to support this possibility.